With respect to the AstraZeneca vaccine, I am guessing people think my objection is to science by press release, and that I want a peer-reviewed publication. But no, not really. What I want is reliable and definitive evidence to inform policies impacting millions. 1/4
-
-
There was a dosing error, and here’s what we’re doing going ahead. Fine. Not this confusion. Not now.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Honestly, I think that this stems from partnering with a relatively inexperienced vaccine manufacturer. (Although technically Moderna has even less, they have also much more actively recruited from established competitors.)
-
At least among innovator companies familiar with the regulatory approval process for entirely new products, that is. And while I like AstraZeneca’s strategy of licensing partnerships to improve global access, the tech transfer demands must have also stretched their team thin.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.